Literature DB >> 2114816

Fibrinogen-fibrin transformation in situ in renal cell carcinoma.

M Z Wojtukiewicz1, L R Zacharski, V A Memoli, W Kisiel, B J Kudryk, S M Rousseau, D C Stump.   

Abstract

The mechanism of coagulation activation in renal cell carcinoma was investigated using immunohistochemical techniques applied to fresh frozen sections of resected primary tumors. Tissue factor antigen was detected in the endothelium of vascular channels within the tumors. Fibrinogen and factor V were distributed diffusely in the perivascular tumor connective tissue. Fibrin was readily detected in a linear pattern along the edges of nodules of viable tumor indicating that thrombin had formed from the interaction of coagulation factors demonstrated previously in renal cell carcinoma tissue. Tissue plasminogen activator was detected in the endothelium of blood vessels in the vicinity of the tumor and urokinase in areas of necrosis but neither were associated with viable tumor cells. These results indicate that thrombin is formed locally in renal cell carcinoma tissue that transforms fibrinogen to fibrin. There also appears to be a net deficit in fibrinolysis in situ in this tumor. We postulate that these conditions might contribute to stabilization and progression of renal cell carcinoma and that clinical trials of antithrombotic agents are justified in this tumor type.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2114816

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

Review 1.  Non-tissue factor procoagulants in cancer cells.

Authors:  S G Gordon; M Chelladurai
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 2.  Anticoagulation, ferrotoxicity and the future of translational lung cancer research.

Authors:  Leo R Zacharski
Journal:  Transl Lung Cancer Res       Date:  2016-06

Review 3.  The hemostatic system and angiogenesis in malignancy.

Authors:  M Z Wojtukiewicz; E Sierko; P Klement; J Rak
Journal:  Neoplasia       Date:  2001 Sep-Oct       Impact factor: 5.715

4.  Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy.

Authors:  Iris Y Sheng; Shilpa Gupta; Chandana A Reddy; Dana Angelini; Pauline Funchain; Tamara A Sussman; Joseph Sleiman; Moshe C Ornstein; Keith McCrae; Alok A Khorana
Journal:  Target Oncol       Date:  2021-11-06       Impact factor: 4.864

Review 5.  Tissue factor as a tumor procoagulant.

Authors:  L V Rao
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 6.  The role of fibrin in tumor metastasis.

Authors:  V Costantini; L R Zacharski
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

7.  Increased PADI4 expression in blood and tissues of patients with malignant tumors.

Authors:  Xiaotian Chang; Jinxiang Han; Li Pang; Yan Zhao; Yi Yang; Zhonglin Shen
Journal:  BMC Cancer       Date:  2009-01-30       Impact factor: 4.430

8.  Hypercoagulability as a prognostic factor for survival in patients with metastatic renal cell carcinoma.

Authors:  Ilya V Tsimafeyeu; Lev V Demidov; Albina V Madzhuga; Oksana V Somonova; Anna L Yelizarova
Journal:  J Exp Clin Cancer Res       Date:  2009-03-02

9.  Heterogeneous Expression of Proangiogenic and Coagulation Proteins in Gliomas of Different Histopathological Grade.

Authors:  Marek Z Wojtukiewicz; Marta Mysliwiec; Elwira Matuszewska; Stanislaw Sulkowski; Lech Zimnoch; Barbara Politynska; Anna M Wojtukiewicz; Stephanie C Tucker; Kenneth V Honn
Journal:  Pathol Oncol Res       Date:  2021-03-31       Impact factor: 3.201

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.